PAPER

Psychiatric disorders in preclinical Huntington’s disease

Camille L Julien¹, Jennifer C Thompson¹, Sue Wild², Pamela Yardumian², Julie S Snowden¹, Gwen Turner², David Craufurd³

¹ Cerebral Function Unit, Greater Manchester Neuroscience Centre, Hope Hospital, Salford, UK
² Department of Clinical Genetics, St James’ Hospital, Leeds, UK
³ Academic Unit of Medical Genetics and Regional Genetic Service, University of Manchester and St Mary’s Hospital, Manchester, UK

Correspondence to:
Dr David Craufurd
Academic Unit of Medical Genetics and Regional Genetic Service, St Mary’s Hospital, Hathersage Road, Manchester M13 0JH, UK; david.craufurd{at}manchester.ac.uk

Background: Psychiatric symptoms are a common feature of Huntington’s disease (HD) and often precede the onset of motor and cognitive impairments. However, it remains unclear whether psychiatric changes in the preclinical period result from structural change, are a reaction to being at risk or simply a coincidental occurrence. Few studies have investigated the temporal course of psychiatric disorder across the preclinical period.

Objectives: To compare lifetime and current prevalence of psychiatric disorder in presymptomatic gene carriers and non-carriers and to examine the relationship of psychiatric prevalence in gene carriers to temporal proximity of clinical onset.

Methods: Lifetime and current psychiatric histories of 204 at risk individuals (89 gene carriers and 115 non-carriers) were obtained using a structured clinical interview, the Composite International Diagnostic Interview. Psychiatric disorders were classified using both standardised diagnostic criteria and a more subtle symptom based approach. Follow-up of gene carriers (n = 51) enabled analysis of the role of temporal proximity to clinical onset.

Results: Gene carriers and non-carriers did not differ in terms of the lifetime frequency of clinical psychiatric disorders or subclinical symptoms. However, gene carriers reported a significantly higher rate of current depressive symptoms. Moreover, the rate of depression increased as a function of proximity to clinical onset.

Conclusions: Affective disorder is an important feature of the prodromal stages of HD. The findings indicate that depression cannot be accounted for by natural concerns of being at risk. There is evidence of a window of several years in which preclinical symptoms are apparent.

Abbreviations: CIDI, Composite International Diagnostic Interview; DSM-III, Diagnostic and Statistical Manual of Mental Disorders 3rd edition; HD, Huntington’s disease; QNE, quantitated neurological examination

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Understanding the psychiatric prodrome of Huntington disease

Adam Rosenblatt
J. Neurol. Neurosurg. Psychiatry 2007 78: 913. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Pouladi, M. A., Graham, R. K., Karasinska, J. M., Xie, Y., Santos, R. D., Petersen, A., Hayden, M. R. (2009). Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 132: 919-932 [Abstract] [Full Text]  
• Pang, T. Y.C., Du, X., Zajac, M. S., Howard, M. L., Hannan, A. J. (2009). Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum Mol Genet 18: 753-766 [Abstract] [Full Text]  
• Rosenblatt, A. (2007). Understanding the psychiatric prodrome of Huntington disease. J. Neurol. Neurosurg. Psychiatry 78: 913-913 [Full Text]